MTOR and cancer: In general, the translational machinery is considered to be a valuable therapeutic target for different cancer entities and can be addressed by the translation elongation inhibitor omacetaxine or mTOR inhibitors, respectively, which are currently tested in numerous clinical cancer studies [65].